• Hapvida flagged a commercial review of loss-making or delinquent contracts covering 947,000 members, about 11% of its health portfolio.
• Review is set to run contract-by-contract at renewal dates over the next 12 months, potentially affecting pricing or continuity for clients.
• ANS was reported in the press to have issued a precautionary order to block double-digit price hikes or cancellations tied to the review.
• Hapvida said it has not received any ANS notice or decision, requested a hearing, plans to provide technical and regulatory explanations.
• No change to the 2Q26 outlook; Hapvida said it sees no undisclosed material fact because it has not been formally notified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hapvida Participações e Investimentos SA published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.